Evidence map›Paper›PMID 31848196›Full record

ArticleCancer research2020

HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

Sayuri Miyauchi, P Dominick Sanders, Kripa Guram, Sangwoo S Kim, Francesca Paolini, Aldo Venuti, Ezra E W Cohen, J Silvio Gutkind, Joseph A Califano, Andrew B Sharabi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sayuri MiyauchiDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
P Dominick SandersDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
Kripa GuramDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
Sangwoo S KimDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
Francesca PaoliniHPV-Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Aldo VenutiHPV-Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0003-2322-6857
Ezra E W CohenMoores Cancer Center, University of California, San Diego, La Jolla, California.
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, California.
Joseph A CalifanoMoores Cancer Center, University of California, San Diego, La Jolla, California.
Andrew B SharabiDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California. Sharabi@ucsd.edu.
University of California San Diego · USNational Cancer Institute · MY

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCCR01DE028563 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHARABI, ANDREW B. · 2019 to 2023
$1.8M
NCATS NIH HHS KL2 TR001444NCI NIH HHS L30 CA231829NCI NIH HHS P30 CA023100NIDCR NIH HHS R01 DE028563NIDCR NIH HHS U01 DE028227
6 · The paper itself

Abstract

There is a critical need to understand mechanisms of resistance and to develop combinatorial strategies to improve responses to checkpoint blockade immunotherapy (CBI). Here, we uncover a novel mechanism by which the human papillomavirus (HPV) inhibits the activity of CBI in head and neck squamous cell carcinoma (HNSCC). Using orthotopic HNSCC models, we show that radiation combined with anti-PD-L1 immunotherapy significantly enhanced local control, CD8

Indexed as

AdolescentAdultAgedAnimalsAntigen PresentationAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCell Line, TumorChemoradiotherapyCohort StudiesDisease Models, AnimalDown-RegulationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanCd274 protein, mouseHistocompatibility Antigens Class IIoncogene protein E5, Human papillomavirus type 16Oncogene Proteins, ViralRimantadineViroporin Proteins

Identifiers

PMID31848196
PMCPMC7024675
OpenAlexW2996146974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.